FirstAlerts
Recalls & Safety Alerts

Vitruvias Therapeutics Expands Recall of Thyroid Tablets, USP 30 mg

The company is recalling an additional lot after testing confirmed the pills may contain more hormone than the label states.

4 reports on this incident · first at Aug 25, 2026, 10:32 a.m. ET

By AI ReporterFirst reported Aug 25, 2026, 10:10 a.m. ETWritten Aug 25, 2026, 10:46 a.m. ET
has expanded its recall of Thyroid Tablets, USP 30 mg to include an additional lot, according to a notice reported by Medical Daily. The recall, initiated on August 21, 2026, is . , the notice states. The affected product was distributed . A total of 1,955 tablets were sold. No reports of adverse events known to be related to the recall have been received, according to Medical Daily. , the notice advises.

Earlier reports

  1. Aug 25, 2026, 10:39 a.m. ET

    FDA Reports Injuries in Ongoing Vitruvias Thyroid Tablets Recall

    The U.S. Food and Drug Administration has received reports of adverse events related to the ongoing recall of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg, according to Medical Daily. The agency did not specify the number or nature of the injuries, and it has not confirmed they are linked to the defect.

    The recall, initiated on August 21, 2026, covers a lot of the tablets distributed nationwide to the company's direct accounts. Testing confirmed the pills may contain more hormone than the label states, which can cause weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances. Approximately 1,955 tablets were sold.

    The FDA advises patients currently taking the product from the recalled lot not to discontinue use without contacting a healthcare provider for guidance or a replacement prescription. The recall status is ongoing.

  2. Aug 25, 2026, 10:35 a.m. ET

    FDA Closes Recall of Vitruvias Thyroid Tablets Over Excess Hormone

    The U.S. Food and Drug Administration has closed the recall of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg, initiated on August 21, 2026, according to Medical Daily. The agency considers the recall carried out.

    The recall was prompted by testing that confirmed the pills may contain more hormone than the label says. The product was distributed nationwide to the company's direct accounts, and 1,955 tablets were sold. No reports of adverse events known to be related to the recall have been reported.

    Patients currently taking product from the recalled lot should not discontinue use without contacting a healthcare provider for guidance or a replacement prescription, according to Medical Daily.

  3. Aug 25, 2026, 10:32 a.m. ETFirst report

    Vitruvias Therapeutics Recalls Thyroid Tablets Over Excess Hormone

    Vitruvias Therapeutics is recalling one lot of Thyroid Tablets, USP 30 mg, distributed nationwide to its direct accounts, according to the U.S. Food and Drug Administration (FDA) as reported by Medical Daily. The recall was initiated on August 21, 2026, and is ongoing.

    The recall was prompted by testing that confirmed the pills may contain more hormone than the label indicates, which could lead to symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances. No adverse events known to be related to the recalled product have been reported.

    A total of 1,955 tablets from the affected lot were sold. Patients currently taking product from the recalled lot should not discontinue use without contacting a healthcare provider for guidance or a replacement prescription, the FDA advised.

Was this report accurate and useful?

Sources

Revision history

  1. Version 125 Aug 2026, 14:46current

    First published.

  2. Version 125 Aug 2026, 14:32current

    First published.

  3. Version 125 Aug 2026, 14:39current

    First published.

  4. Version 125 Aug 2026, 14:35current

    First published.

How we work

This site models an investigative reporter rather than a wire desk. The aim is the most complete, accurate and timely account we can assemble — all three, not a trade between them. Reports go out within minutes of the coverage they are built from, carrying context a newsroom would otherwise need a day and a records request to gather: what has happened at this place before, what the operator’s record is, which aircraft it actually was.

Reports are built from primary sources — accident and court records, official registries, weather observations, agency statements — and from reputable news organisations, each named where their reporting is used. Facts are extracted before anything is written, and every one must be supported by a quotation found in the source itself; the model that writes the report is given only those verified facts and never sees the article, so it cannot introduce a detail no source stated.

Where sources disagree we publish the disagreement, attributed, rather than picking a figure. Where a fact comes from a record rather than a reporter, we say so, and the language matches: an instrument reading is never described as something anyone confirmed. Some things are deliberately withheld — a suspect is not named until an agency names them on the record, victims until families or officials release them — and corrections appear as visible revisions, never as silent edits.

None of that makes a report true. A quotation check proves a source said something, not that it was right, and an automated system can be confidently wrong in ways the checks do not catch. If something here is wrong, the feedback above is how it gets found. The full methodology, including what we refuse to publish.